GERD is another important disease in which CYP2C19 genotyping is relevant since, in this disease, there are subjects who are refractory to PPIs, which means they have a persistence of symptoms after eight weeks of treatment with double doses of PPIs [26]. Here, CYP2C19 is linked to gastroesophageal reflux disease.